Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

IDEAYA/Servier PKC drug aces uveal melanoma trial

 April 13, 2026

Pharmaphorum

Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

Clinical DataOncologyRead full story

Post navigation

AbbVie enters world of pain in up to $715M deal with China’s Haisco →
← IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com